Sidera Bio

Executive Summary

Sidera Bio is a Copenhagen-based biotechnology company founded in 2020 that leverages human genetics to develop transformative therapies for cardiometabolic diseases. By integrating CRISPR, genomics, and diagnostics, the company translates genetic insights into novel drug targets, aiming to address high unmet medical needs. As a private entity with limited public disclosures, Sidera Bio remains in early stages of research and development, focusing on target identification and lead optimization. Its dual presence in Denmark and Cambridge, Massachusetts provides access to leading scientific talent and collaborative ecosystems. The company's pipeline is not yet publicly detailed, but its technology platform holds promise for precision medicine approaches in cardiometabolic disorders such as dyslipidemia, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Sidera Bio's approach could yield first-in-class or best-in-class therapies by targeting genetically validated pathways. However, the absence of disclosed funding rounds, partnerships, or clinical-stage programs suggests the company is at a pre-clinical or early research stage, with significant execution risk ahead. The management team's experience and the robustness of the genetic validation will be critical to advancing programs toward the clinic.

Upcoming Catalysts (preview)

• Q2 2026Lead Program IND-Enabling Studies Initiation60% success
• Q3 2026Series A or Seed Funding Announcement70% success
• Q4 2026First Pipeline Program Public Disclosure50% success